Search

Your search keyword '"Naganuma, Atsushi"' showing total 520 results
Start Over Author "Naganuma, Atsushi"
520 results on '"Naganuma, Atsushi"'

102. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Saito, Naoto, additional, Nakano, Yuya, additional, Nakano, Sachi, additional, Hazama, Yoichi, additional, Yoshida, Sachiko, additional, Hachisu, Yoko, additional, Tanaka, Yoshiki, additional, Kashiwabara, Kenji, additional, Yoshinaga, Teruo, additional, Tojima, Hiroki, additional, Naganuma, Atsushi, additional, and Uraoka, Toshio, additional

Published
2021
Full Text
View/download PDF

103. Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals

Author

Takakusagi, Satoshi, primary, Saito, Naoto, additional, Ueno, Takashi, additional, Hatanaka, Takeshi, additional, Namikawa, Masashi, additional, Tojima, Hiroki, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Kosone, Takashi, additional, Arai, Hirotaka, additional, Sato, Ken, additional, Kakizaki, Satoru, additional, Takagi, Hitoshi, additional, and Uraoka, Toshio, additional

Published
2021
Full Text
View/download PDF

104. The first reported case of Noonan syndrome complicated with hepatocellular carcinoma

Author

Kakizaki, Satoru, primary, Uehara, Daisuke, additional, Tojima, Hiroki, additional, Suga, Takayoshi, additional, Yamazaki, Yuichi, additional, Sato, Ken, additional, Kubo, Norio, additional, Shirabe, Ken, additional, Yokota, Takayuki, additional, Shibuya, Kei, additional, Maehara, Tatsurou, additional, Yokoo, Hideaki, additional, Naganuma, Atsushi, additional, and Uraoka, Toshio, additional

Published
2021
Full Text
View/download PDF

105. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Author

Asselta, Rosanna, primary, Paraboschi, Elvezia M., additional, Gerussi, Alessio, additional, Cordell, Heather J., additional, Mells, George F., additional, Sandford, Richard N., additional, Jones, David E., additional, Nakamura, Minoru, additional, Ueno, Kazuko, additional, Hitomi, Yuki, additional, Kawashima, Minae, additional, Nishida, Nao, additional, Tokunaga, Katsushi, additional, Nagasaki, Masao, additional, Tanaka, Atsushi, additional, Tang, Ruqi, additional, Li, Zhiqiang, additional, Shi, Yongyong, additional, Liu, Xiangdong, additional, Xiong, Ma, additional, Hirschfield, Gideon, additional, Siminovitch, Katherine A., additional, Carbone, Marco, additional, Cardamone, Giulia, additional, Duga, Stefano, additional, Gershwin, M. Eric, additional, Seldin, Michael F., additional, Invernizzi, Pietro, additional, Walker, Erin, additional, Xie, Gang, additional, Mason, Andy, additional, Myers, Robert, additional, Peltekian, Kevork, additional, Ghent, Cameron, additional, Atkinson, Elizabeth, additional, Juran, Bruce, additional, Lazaridis, Kostas, additional, Lu, Yue, additional, Gu, Xiangjun, additional, Jing, Kaiyan, additional, Amos, Chris, additional, Affronti, Andrea, additional, Brunetto, Maurizia, additional, Coco, Barbara, additional, Spinzi, Giancarlo, additional, Elia, Gianfranco, additional, Ferrari, Carlo, additional, Lleo, Ana, additional, Muratori, Luigi, additional, Muratori, Paolo, additional, Portincasa, Piero, additional, Colli, Agostino, additional, Bruno, Savino, additional, Colloredo, Guido, additional, Azzaroli, Francesco, additional, Andreone, Pietro, additional, Bragazzi, MariaConsiglia, additional, Alvaro, Domenico, additional, Cardinale, Vincenzo, additional, Cazzagon, Nora, additional, Rigamonti, Cristina, additional, Floreani, Annarosa, additional, Rosina, Floriano, additional, Ciaccio, Antonio, additional, Cristoferi, Laura, additional, D’Amato, Daphne, additional, Malinverno, Federica, additional, Mancuso, Clara, additional, Massironi, Sara, additional, Milani, Chiara, additional, O’Donnell, Sarah E., additional, Ronca, Vincenzo, additional, Barisani, Donatella, additional, Lampertico, Pietro, additional, Donato, Francesca, additional, Fagiuoli, Stefano, additional, Almasio, Piero L., additional, Giannini, Edoardo, additional, Cursaro, Carmela, additional, Colombo, Massimo, additional, Valenti, Luca, additional, Miele, Luca, additional, Andriulli, Angelo, additional, Niro, Grazia A., additional, Grattagliano, Ignazio, additional, Morini, Lorenzo, additional, Casella, Giovanni, additional, Vinci, Maria, additional, Battezzati, Pier Maria, additional, Crosignani, Andrea, additional, Zuin, Massimo, additional, Mattalia, Alberto, additional, Calvaruso, Vincenza, additional, Colombo, Silvia, additional, Benedetti, Antonio, additional, Marzioni, Marco, additional, Galli, Andrea, additional, Marra, Fabio, additional, Tarocchi, Mirko, additional, Picciotto, Antonio, additional, Morisco, Filomena, additional, Fabris, Luca, additional, Crocè, Lory Saveria, additional, Tiribelli, Claudio, additional, Toniutto, Pierluigi, additional, Strazzabosco, Mario, additional, Ch’ng, Chin Lye, additional, Rahman, Mesbah, additional, Yapp, Tom, additional, Sturgess, Richard, additional, Healey, Christopher, additional, Czajkowski, Marek, additional, Gunasekera, Anton, additional, Gyawali, Pranab, additional, Premchand, Purushothaman, additional, Kapur, Kapil, additional, Marley, Richard, additional, Foster, Graham, additional, Watson, Alan, additional, Dias, Aruna, additional, Subhani, Javaid, additional, Harvey, Rory, additional, McCorry, Roger, additional, Ramanaden, David, additional, Gasem, Jaber, additional, Evans, Richard, additional, Mathialahan, Thiriloganathan, additional, Shorrock, Christopher, additional, Lipscomb, George, additional, Southern, Paul, additional, Tibble, Jeremy, additional, Gorard, David, additional, Palegwala, Altaf, additional, Jones, Susan, additional, Dawwas, Mohamed, additional, Alexander, Graeme, additional, Dolwani, Sunil, additional, Prince, Martin, additional, Foxton, Matthew, additional, Elphick, David, additional, Mitchison, Harriet, additional, Gooding, Ian, additional, Karmo, Mazn, additional, Saksena, Sushma, additional, Mendall, Mike, additional, Patel, Minesh, additional, Ede, Roland, additional, Austin, Andrew, additional, Sayer, Joanna, additional, Hankey, Lorraine, additional, Hovell, Christopher, additional, Fisher, Neil, additional, Carter, Martyn, additional, Koss, Konrad, additional, Piotrowicz, Andrzej, additional, Grimley, Charles, additional, Neal, David, additional, Lim, Guan, additional, Levi, Sass, additional, Ala, Aftab, additional, Broad, Andrea, additional, Saeed, Athar, additional, Wood, Gordon, additional, Brown, Jonathan, additional, Wilkinson, Mark, additional, Gordon, Harriet, additional, Ramage, John, additional, Ridpath, Jo, additional, Ngatchu, Theodore, additional, Grover, Bob, additional, Shaukat, Syed, additional, Shidrawi, Ray, additional, Abouda, George, additional, Ali, Faiz, additional, Rees, Ian, additional, Salam, Imroz, additional, Narain, Mark, additional, Brown, Ashley, additional, Taylor-Robinson, Simon, additional, Williams, Simon, additional, Grellier, Leonie, additional, Banim, Paul, additional, Das, Debasish, additional, Chilton, Andrew, additional, Heneghan, Michael, additional, Curtis, Howard, additional, Gess, Markus, additional, Drake, Ian, additional, Aldersley, Mark, additional, Davies, Mervyn, additional, Jones, Rebecca, additional, McNair, Alastair, additional, Srirajaskanthan, Raj, additional, Pitcher, Maxton, additional, Sen, Sambit, additional, Bird, George, additional, Barnardo, Adrian, additional, Kitchen, Paul, additional, Yoong, Kevin, additional, Chirag, Oza, additional, Sivaramakrishnan, Nurani, additional, MacFaul, George, additional, Jones, David, additional, Shah, Amir, additional, Evans, Chris, additional, Saha, Subrata, additional, Pollock, Katharine, additional, Bramley, Peter, additional, Mukhopadhya, Ashis, additional, Fraser, Andrew, additional, Mills, Peter, additional, Shallcross, Christopher, additional, Campbell, Stewart, additional, Bathgate, Andrew, additional, Shepherd, Alan, additional, Dillon, John, additional, Rushbrook, Simon, additional, Przemioslo, Robert, additional, Macdonald, Christopher, additional, Metcalf, Jane, additional, Shmueli, Udi, additional, Davis, Andrew, additional, Naqvi, Asifabbas, additional, Lee, Tom, additional, Ryder, Stephen D., additional, Collier, Jane, additional, Klass, Howard, additional, Ninkovic, Mary, additional, Cramp, Matthew, additional, Sharer, Nicholas, additional, Aspinall, Richard, additional, Goggin, Patrick, additional, Ghosh, Deb, additional, Douds, Andrew, additional, Hoeroldt, Barbara, additional, Booth, Jonathan, additional, Williams, Earl, additional, Hussaini, Hyder, additional, Stableforth, William, additional, Ayres, Reuben, additional, Thorburn, Douglas, additional, Marshall, Eileen, additional, Burroughs, Andrew, additional, Mann, Steven, additional, Lombard, Martin, additional, Richardson, Paul, additional, Patanwala, Imran, additional, Maltby, Julia, additional, Brookes, Matthew, additional, Mathew, Ray, additional, Vyas, Samir, additional, Singhal, Saket, additional, Gleeson, Dermot, additional, Misra, Sharat, additional, Butterworth, Jeff, additional, George, Keith, additional, Harding, Tim, additional, Douglass, Andrew, additional, Panter, Simon, additional, Shearman, Jeremy, additional, Bray, Gary, additional, Butcher, Graham, additional, Forton, Daniel, additional, Mclindon, John, additional, Cowan, Matthew, additional, Whatley, Gregory, additional, Mandal, Aditya, additional, Gupta, Hemant, additional, Sanghi, Pradeep, additional, Jain, Sanjiv, additional, Pereira, Steve, additional, Prasad, Geeta, additional, Watts, Gill, additional, Wright, Mark, additional, Neuberger, James, additional, Gordon, Fiona, additional, Unitt, Esther, additional, Grant, Allister, additional, Delahooke, Toby, additional, Higham, Andrew, additional, Brind, Alison, additional, Cox, Mark, additional, Ramakrishnan, Subramaniam, additional, King, Alistair, additional, Collins, Carole, additional, Whalley, Simon, additional, Li, Andy, additional, Fraser, Jocelyn, additional, Bell, Andrew, additional, Wong, Voi Shim, additional, Singhal, Amit, additional, Gee, Ian, additional, Ang, Yeng, additional, Ransford, Rupert, additional, Gotto, James, additional, Millson, Charles, additional, Bowles, Jane, additional, Thomas, Caradog, additional, Harrison, Melanie, additional, Galaska, Roman, additional, Kendall, Jennie, additional, Whiteman, Jessica, additional, Lawlor, Caroline, additional, Gray, Catherine, additional, Elliott, Keith, additional, Mulvaney-Jones, Caroline, additional, Hobson, Lucie, additional, Van Duyvenvoorde, Greta, additional, Loftus, Alison, additional, Seward, Katie, additional, Penn, Ruth, additional, Maiden, Jane, additional, Damant, Rose, additional, Hails, Janeane, additional, Cloudsdale, Rebecca, additional, Silvestre, Valeria, additional, Glenn, Sue, additional, Dungca, Eleanor, additional, Wheatley, Natalie, additional, Doyle, Helen, additional, Kent, Melanie, additional, Hamilton, Caroline, additional, Braim, Delyth, additional, Wooldridge, Helen, additional, Abrahams, Rachel, additional, Paton, Alison, additional, Lancaster, Nicola, additional, Gibbins, Andrew, additional, Hogben, Karen, additional, Desousa, Phillipa, additional, Muscariu, Florin, additional, Musselwhite, Janine, additional, McKay, Alexandra, additional, Tan, LaiTing, additional, Foale, Carole, additional, Brighton, Jacqueline, additional, Flahive, Kerry, additional, Nambela, Estelle, additional, Townshend, Paula, additional, Ford, Chris, additional, Holder, Sophie, additional, Palmer, Caroline, additional, Featherstone, James, additional, Nasseri, Mariam, additional, Sadeghian, Joy, additional, Williams, Bronwen, additional, Thomas, Carol, additional, Rolls, Sally-Ann, additional, Hynes, Abigail, additional, Duggan, Claire, additional, Jones, Sarah, additional, Crossey, Mary, additional, Stansfield, Glynis, additional, MacNicol, Carolyn, additional, Wilkins, Joy, additional, Wilhelmsen, Elva, additional, Raymode, Parizade, additional, Lee, Hye-Jeong, additional, Durant, Emma, additional, Bishop, Rebecca, additional, Ncube, Noma, additional, Tripoli, Sherill, additional, Casey, Rebecca, additional, Cowley, Caroline, additional, Miller, Richard, additional, Houghton, Kathryn, additional, Ducker, Samantha, additional, Wright, Fiona, additional, Bird, Bridget, additional, Baxter, Gwen, additional, Keggans, Janie, additional, Hughes, Maggie, additional, Grieve, Emma, additional, Young, Karin, additional, Williams, D., additional, Ocker, Kate, additional, Hines, Frances, additional, Martin, Kirsty, additional, Innes, Caron, additional, Valliani, Talal, additional, Fairlamb, Helen, additional, Thornthwaite, Sarah, additional, Eastick, Anne, additional, Tanqueray, Elizabeth, additional, Morrison, Jennifer, additional, Holbrook, Becky, additional, Browning, Julie, additional, Walker, Kirsten, additional, Congreave, Susan, additional, Verheyden, Juliette, additional, Slininger, Susan, additional, Stafford, Lizzie, additional, O’Donnell, Denise, additional, Ainsworth, Mark, additional, Lord, Susan, additional, Kent, Linda, additional, March, Linda, additional, Dickson, Christine, additional, Simpson, Diane, additional, Longhurst, Beverley, additional, Hayes, Maria, additional, Shpuza, Ervin, additional, White, Nikki, additional, Besley, Sarah, additional, Pearson, Sallyanne, additional, Wright, Alice, additional, Jones, Linda, additional, Gunter, Emma, additional, Dewhurst, Hannah, additional, Fouracres, Anna, additional, Farrington, Liz, additional, Graves, Lyn, additional, Marriott, Suzie, additional, Leoni, Marina, additional, Tyrer, David, additional, Martin, Kate, additional, Dali-kemmery, Lola, additional, Lambourne, Victoria, additional, Green, Marie, additional, Sirdefield, Dawn, additional, Amor, Kelly, additional, Colley, Julie, additional, Shinder, Bal, additional, Jones, Jayne, additional, Mills, Marisa, additional, Carnahan, Mandy, additional, Taylor, Natalie, additional, Boulton, Kerenza, additional, Tregonning, Julie, additional, Brown, Carly, additional, Clifford, Gayle, additional, Archer, Emily, additional, Hamilton, Maria, additional, Curtis, Janette, additional, Shewan, Tracey, additional, Walsh, Sue, additional, Warner, Karen, additional, Netherton, Kimberley, additional, Mupudzi, Mcdonald, additional, Gunson, Bridget, additional, Gitahi, Jane, additional, Gocher, Denise, additional, Batham, Sally, additional, Pateman, Hilary, additional, Desmennu, Senayon, additional, Conder, Jill, additional, Clement, Darren, additional, Gallagher, Susan, additional, Orpe, Jacky, additional, Chan, PuiChing, additional, Currie, Lynn, additional, O’Donohoe, Lynn, additional, Oblak, Metod, additional, Morgan, Lisa, additional, Quinn, Marie, additional, Amey, Isobel, additional, Baird, Yolanda, additional, Cotterill, Donna, additional, Cumlat, Lourdes, additional, Winter, Louise, additional, Greer, Sandra, additional, Spurdle, Katie, additional, Allison, Joanna, additional, Dyer, Simon, additional, Sweeting, Helen, additional, Kordula, Jean, additional, Aiba, Yoshihiro, additional, Nakamura, Hitomi, additional, Abiru, Seigo, additional, Nagaoka, Shinya, additional, Komori, Atsumasa, additional, Yatsuhashi, Hiroshi, additional, Ishibashi, Hiromi, additional, Ito, Masahiro, additional, Kawai, Yosuke, additional, Kohn, Seik-Soon, additional, Gervais, Olivier, additional, Migita, Kiyoshi, additional, Katsushima, Shinji, additional, Naganuma, Atsushi, additional, Sugi, Kazuhiro, additional, Komatsu, Tatsuji, additional, Mannami, Tomohiko, additional, Matsushita, Kouki, additional, Yoshizawa, Kaname, additional, Makita, Fujio, additional, Nikami, Toshiki, additional, Nishimura, Hideo, additional, Kouno, Hiroshi, additional, Kouno, Hirotaka, additional, Ota, Hajime, additional, Komura, Takuya, additional, Nakamura, Yoko, additional, Shimada, Masaaki, additional, Hirashima, Noboru, additional, Komeda, Toshiki, additional, Ario, Keisuke, additional, Nakamuta, Makoto, additional, Yamashita, Tsutomu, additional, Furuta, Kiyoshi, additional, Kikuchi, Masahiro, additional, Naeshiro, Noriaki, additional, Takahashi, Hironao, additional, Mano, Yutaka, additional, Tsunematsu, Seiji, additional, Yabuuchi, Iwao, additional, Shimada, Yusuke, additional, Yamauchi, Kazuhiko, additional, Sugimoto, Rie, additional, Sakai, Hironori, additional, Mita, Eiji, additional, Koda, Masaharu, additional, Tsuruta, Satoru, additional, Kamitsukasa, Hiroshi, additional, Sato, Takeaki, additional, Masaki, Naohiko, additional, Kobata, Tatsuro, additional, Fukushima, Nobuyoshi, additional, Higuchi, Nobito, additional, Ohara, Yukio, additional, Muro, Toyokichi, additional, Takesaki, Eiichi, additional, Takaki, Hitoshi, additional, Yamamoto, Tetsuo, additional, Kato, Michio, additional, Nagaoki, Yuko, additional, Hayashi, Shigeki, additional, Ishida, Jinya, additional, Watanabe, Yukio, additional, Kobayashi, Masakazu, additional, Koga, Michiaki, additional, Saoshiro, Takeo, additional, Yagura, Michiyasu, additional, Hirata, Keisuke, additional, Takikawa, Hajime, additional, Ohira, Hiromasa, additional, Zeniya, Mikio, additional, Abe, Masanori, additional, Onji, Morikazu, additional, Kaneko, Shuichi, additional, Honda, Masao, additional, Arai, Kuniaki, additional, Arinaga-Hino, Teruko, additional, Hashimoto, Etsuko, additional, Taniai, Makiko, additional, Umemura, Takeji, additional, Joshita, Satoru, additional, Nakao, Kazuhiko, additional, Ichikawa, Tatsuki, additional, Shibata, Hidetaka, additional, Yamagiwa, Satoshi, additional, Seike, Masataka, additional, Honda, Koichi, additional, Sakisaka, Shotaro, additional, Takeyama, Yasuaki, additional, Harada, Masaru, additional, Senju, Michio, additional, Yokosuka, Osamu, additional, Kanda, Tatsuo, additional, Ueno, Yoshiyuki, additional, Kikuchi, Kentaro, additional, Ebinuma, Hirotoshi, additional, Himoto, Takashi, additional, Yasunami, Michio, additional, Murata, Kazumoto, additional, Mizokami, Masashi, additional, Shimoda, Shinji, additional, Miyake, Yasuhiro, additional, Takaki, Akinobu, additional, Yamamoto, Kazuhide, additional, Hirano, Katsuji, additional, Ichida, Takafumi, additional, Ido, Akio, additional, Tsubouchi, Hirohito, additional, Chayama, Kazuaki, additional, Harada, Kenichi, additional, Nakanuma, Yasuni, additional, Maehara, Yoshihiko, additional, Taketomi, Akinobu, additional, Shirabe, Ken, additional, Soejima, Yuji, additional, Mori, Akira, additional, Yagi, Shintaro, additional, Uemoto, Shinji, additional, Tanaka, Tomohiro, additional, Yamashiki, Noriyo, additional, Tamura, Sumito, additional, Sugawara, Yasuhiro, additional, and Kokudo, Norihiro, additional

Published
2021
Full Text
View/download PDF

108. Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Author

Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kaibori, Masaki, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Kosaka, Hisashi, Hiasa, Yoichi, and Kudo, Masatoshi

Abstract

Background/Aim:There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. Materials/Methods:From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle volume data obtained by computed tomography at the baseline available were analyzed (median age, 74 years; males, 186 (81.2%); ECOG PS 0/1, 221 (96.5%); HCV:HBV:alcohol:others = 81:33:40:75; Child-Pugh A, 212 (92.6%); modified albumin-bilirubin (mALBI) grade 1:2a:2b = 79:60:90; BCLC 0:A:B:C = 1:24:87:117; median observation period, 6.8 months). Japan Society of Hepatology criteria were used for definition of MVL and prognostic factors were retrospectively evaluated. Results:Multivariate Cox-hazard analysis of prognostic factors for progression-free survival (PFS) showed elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 1.848, 95% CI 1.264–2.702, p= 0.002), mALBI grade (≥2a) (HR 1.563, 95% CI 1.035–2.359, p= 0.034), and MVL (HR 1.479, 95% CI 1.020–2.144, p= 0.039) as significant factors. For overall survival (OS), significant factors included elevated AFP (≥100 ng/mL) (HR 3.564, 95% CI 1.856–6.844, p< 0.001), mALBI grade (≥2a) (HR 3.451, 95% CI 1.580–7.538, p= 0.002), and MVL (HR 2.119, 95% CI 1.150–3.904, p= 0.016). Patients with MVL (MVL group, n= 91) showed worse PFS than those without (non-MVL group, n= 138) (median PFS 5.3 vs. 7.6 months, p= 0.025), while the MVL group showed worse OS (p= 0.038), though neither reached the median survival time. Conclusion:MVL may be a clinical factor related to poor prognosis in patients receiving Atez/Bev treatment for u-HCC.

Published
2022
Full Text
View/download PDF

109. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.

Author

Yasuoka, Hidetoshi, Naganuma, Atsushi, Kurihara, Eishin, Kobatake, Tsutomu, Ijima, Masashi, Tamura, Yuki, Suzuki, Yuhei, Hoshino, Takashi, Ishida, Fumiya, Hosaka, Hisashi, Hatanaka, Takeshi, Yoshida, Sachiko, Aihara, Ryusuke, Hosouchi, Yasuo, Ishii, Norihiro, Araki, Kenichiro, Shirabe, Ken, Uraoka, Toshio, and Kakizaki, Satoru

Subjects
*DRUG efficacy, *FOLINIC acid, *PANCREATIC tumors, *COMBINATION drug therapy, *IRINOTECAN, *RETROSPECTIVE studies, *NEUTROPENIA, *FLUOROURACIL, *NEUTROPHIL lymphocyte ratio, *DESCRIPTIVE statistics, *SURVIVAL analysis (Biometry), *PROGRESSION-free survival, *PATIENT safety, *PHARMACODYNAMICS
Abstract

Introduction: This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/l-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions. Methods: Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/l-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated. Results: The median age was 68 (interquartile range 62–73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line or later treatment. The median overall survival (OS) and progression-free survival were 9.0 (range, 0.7–15.4) months and 4.4 (range, 0.6–15.4) months, respectively. The overall response rate was 5.3%. The disease control rate was 44.7%. Patients with a neutrophil-to-lymphocyte ratio of ≥2.7 had a significant risk of a poor OS (HR = 0.275, p = 0.017). Adverse events were manageable, although gastrointestinal symptoms and neutropenia were observed. The most common grade ≥3 adverse event was neutropenia, which was reported in 20% of patients. Conclusions: Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

110. Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia

Author

Horiguchi, Suguru, primary, Naganuma, Atsushi, additional, Tateyama, Yumeo, additional, Suzuki, Yuhei, additional, Hoshino, Takashi, additional, Saito, Naoto, additional, Hatanaka, Takeshi, additional, Takakusagi, Satoshi, additional, Kosone, Takashi, additional, Takagi, Hitoshi, additional, Uraoka, Toshio, additional, and Kakizaki, Satoru, additional

Published
2021
Full Text
View/download PDF

111. THU-131 - Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

Author

Iavarone, Massimo, Alimenti, Eleonora, Tada, Toshifumi, Shigeo, Shimose, Suda, Goki, Yoo, Changhoon, Soldà, Caterina, Piscaglia, Fabio, Gardini, Andrea Casadei, Marra, Fabio, Vivaldi, Caterina, Conti, Fabio, Schirripa, Marta, Iwamoto, Hideki, Sho, Takuya, Leo, So Heun, Rizzato, Mario Domenico, Tonnini, Matteo, Rimini, Margherita, Campani, Claudia, Masi, Gianluca, Foschi, Francesco, Bruccoleri, Mariangela, Kawaguchi, Takumi, Kumada, Takashi, Hiraoka, Atsushi, Atsukawa, Masanori, Fukunishi, Shinya, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Kawata, Kazuhito, Tada, Faujimasa, Ohama, Hideko, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Tosetti, Giulia, and Lampertico, Pietro

Published
2023
Full Text
View/download PDF

114. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Nagashima, Tamon, additional, Namikawa, Masashi, additional, Ueno, Takashi, additional, Tojima, Hiroki, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Arai, Hirotaka, additional, Harimoto, Norifumi, additional, Shirabe, Ken, additional, and Uraoka, Toshio, additional

Published
2021
Full Text
View/download PDF

115. Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Author

Maruki, Yuta, primary, Morizane, Chigusa, additional, Arai, Yasuhito, additional, Ikeda, Masafumi, additional, Ueno, Makoto, additional, Ioka, Tatsuya, additional, Naganuma, Atsushi, additional, Furukawa, Masayuki, additional, Mizuno, Nobumasa, additional, Uwagawa, Tadashi, additional, Takahara, Naminatsu, additional, Kanai, Masashi, additional, Asagi, Akinori, additional, Shimizu, Satoshi, additional, Miyamoto, Atsushi, additional, Yukisawa, Seigo, additional, Kadokura, Makoto, additional, Kojima, Yasushi, additional, Furuse, Junji, additional, Nakajima, Takako Eguchi, additional, Sudo, Kentaro, additional, Kobayashi, Noritoshi, additional, Hama, Natsuko, additional, Yamanaka, Takeharu, additional, Shibata, Tatsuhiro, additional, and Okusaka, Takuji, additional

Published
2020
Full Text
View/download PDF

116. Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis

Author

Migita, Kiyoshi, primary, Nakamura, Minoru, additional, Aiba, Yoshihiro, additional, Kozuru, Hideko, additional, Abiru, Seigo, additional, Komori, Atsumasa, additional, Fujita, Yuya, additional, Temmoku, Junpei, additional, Asano, Tomoyuki, additional, Sato, Shuzo, additional, Furuya, Makiko, additional, Naganuma, Atsushi, additional, Yoshizawa, Kaname, additional, Shimada, Masaaki, additional, Ario, Keisuke, additional, Mannami, Tomohiko, additional, Kohno, Hiroshi, additional, Kaneyoshi, Toshihiko, additional, Komura, Takuya, additional, Ohira, Hiromasa, additional, and Yatsuhashi, Hiroshi, additional

Published
2020
Full Text
View/download PDF

117. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study

Author

Hatanaka, Takeshi, primary, Naganuma, Atsushi, additional, Shibasaki, Mitsuhiko, additional, Kohga, Tatsuya, additional, Arai, Yosuke, additional, Nagashima, Tamon, additional, Ueno, Takashi, additional, Namikawa, Masashi, additional, Saito, Shuichi, additional, Hoshino, Takashi, additional, Takizawa, Daichi, additional, Arai, Hirotaka, additional, Makita, Fujio, additional, Kakizaki, Satoru, additional, Harimoto, Norifumi, additional, Shirabe, Ken, additional, and Uraoka, Toshio, additional

Published
2020
Full Text
View/download PDF

118. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Author

Shimose, Shigeo, Saeki, Issei, Tomonari, Tetsu, Ito, Takanori, Tani, Joji, Takeuchi, Yasuto, Yoshioka, Naoki, Naito, Takehito, Takeuchi, Mamiko, Kakizaki, Satoru, Hatanaka, Takeshi, Sasaki, Kyo, Yasunaka, Tetsuya, Sakata, Masahiro, Iwamoto, Hideki, Itano, Satoshi, Shirono, Tomotake, Tanabe, Norikazu, Yamamoto, Takafumi, and Naganuma, Atsushi

Subjects
HEPATOCELLULAR carcinoma, DECISION making, PROGRESSION-free survival, DECISION trees, CLINICAL deterioration, HEPATIC veno-occlusive disease
Abstract

Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world clinical practice are unclear. The present study aimed to evaluate the efficacy and safety of Dur/Tre treatment. This multicenter study was conducted between March 2023 and January 2024, and included 120 patients with u-HCC treated with Dur/Tre. Among the patients, 44 had no history of systemic treatment. Progression-free survival (PFS), therapeutic response and adverse events (AEs) were assessed. The objective response rate (ORR) and disease control rates (DCR) were 15.8 and 53.3%, respectively. The median PFS was 3.9 months. The incidence rates of AEs of any grade and those grade 3 or higher were 83.3 and 36.7%, respectively. Liver injury was the most frequent AE of any grade and grade 3 or higher. Although there was no significant difference in ORR and PFS between the first and later line groups (ORR 15.8 vs. 15.7%, P=0.986; PFS 4.5 vs. 3.6 months, P=0.213), there was a significant difference in DCR between the two groups (65.8 vs. 45.9%, P=0.034). No significant differences were noted between the first- and later-line treatment groups regarding the incidence rate of AEs. Decision tree analysis revealed that poor liver function and advanced age were significant variables for discontinuation owing to AEs. In conclusion, Dur/Tre as first-line therapy had better disease control responses compared with later-line therapy; however, this regimen should be carefully administered to patients with deteriorating hepatic function or advanced age. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

121. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Nagashima, Tamon, additional, Namikawa, Masashi, additional, Ueno, Takashi, additional, Tojima, Hiroki, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Arai, Hirotaka, additional, Sato, Ken, additional, Harimoto, Norifumi, additional, Shirabe, Ken, additional, and Uraoka, Toshio, additional

Published
2020
Full Text
View/download PDF

122. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab

Author

Naganuma, Atsushi, primary, Sakuda, Takayoshi, additional, Murakami, Tatsuma, additional, Aihara, Kosuke, additional, Watanuki, Yuta, additional, Suzuki, Yuhei, additional, Shibasaki, Erina, additional, Masuda, Tomoyuki, additional, Uehara, Sanae, additional, Yasuoka, Hidetoshi, additional, Hoshino, Takashi, additional, Kudo, Tomohiro, additional, Ishihara, Hiroshi, additional, Ogawa, Tetsushi, additional, Kitamoto, Yoshizumi, additional, and Ogawa, Akira, additional

Published
2020
Full Text
View/download PDF

123. Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain

Author

Yamazaki, Yuichi, primary, Uehara, Daisuke, additional, Kanayama, Yuki, additional, Suga, Takayoshi, additional, Ueno, Takashi, additional, Hatanaka, Takeshi, additional, Takakusagi, Satoshi, additional, Tojima, Hiroki, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Kosone, Takashi, additional, Nakajima, Hiroaki, additional, Sato, Ken, additional, Kakizaki, Satoru, additional, Takagi, Hitoshi, additional, Uraoka, Toshio, additional, Takahashi, Masaharu, additional, Nagashima, Shigeo, additional, and Okamoto, Hiroaki, additional

Published
2020
Full Text
View/download PDF

124. Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Author

Takaoka, Yoshinari, primary, Miura, Kouichi, additional, Morimoto, Naoki, additional, Kakizaki, Satoru, additional, Ikegami, Tadashi, additional, Ueno, Takashi, additional, Arai, Hirotaka, additional, Hatanaka, Takeshi, additional, Tahara, Toshiyuki, additional, Murohisa, Toshimitsu, additional, Namikawa, Masashi, additional, Naganuma, Atsushi, additional, Ohtake, Takaaki, additional, Horiuchi, Katsuhiko, additional, Asano, Takeharu, additional, Kamoshida, Toshiro, additional, Tano, Shigeo, additional, Fukaya, Yukimura, additional, Kosone, Takashi, additional, Watanabe, Shunji, additional, Tsukui, Mamiko, additional, Hirosawa, Takuya, additional, Nomoto, Hiroaki, additional, Goka, Rie, additional, Maeda, Hiroshi, additional, Sato, Naoto, additional, Isoda, Norio, additional, and Yamamoto, Hironori, additional

Published
2020
Full Text
View/download PDF

125. Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy

Author

Shibasaki, Mitsuhiko, primary, Hatanaka, Takeshi, additional, Shimada, Yasushi, additional, Nagashima, Tamon, additional, Namikawa, Masashi, additional, Saito, Shuichi, additional, Hosonuma, Kenichi, additional, Naganuma, Atsushi, additional, Takizawa, Daichi, additional, Arai, Hirotaka, additional, Kosone, Takashi, additional, Takagi, Hitoshi, additional, Sato, Ken, additional, Kakizaki, Satoru, additional, and Uraoka, Toshio, additional

Published
2020
Full Text
View/download PDF

126. Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure

Author

Tojima, Hiroki, primary, Kakizaki, Satoru, additional, Takakusagi, Satoshi, additional, Hoshino, Takashi, additional, Naganuma, Atsushi, additional, Nagashima, Tamon, additional, Namikawa, Masashi, additional, Ueno, Takashi, additional, Shimada, Yasushi, additional, Hatanaka, Takeshi, additional, Takizawa, Daichi, additional, Arai, Hirotaka, additional, Sato, Ken, additional, Takagi, Hitoshi, additional, and Uraoka, Toshio, additional

Published
2019
Full Text
View/download PDF

127. Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Nagashima, Tamon, additional, Namikawa, Masashi, additional, Tojima, Hiroki, additional, Shimada, Yasushi, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Arai, Hirotaka, additional, Sato, Ken, additional, Harimoto, Norifumi, additional, Shirabe, Ken, additional, and Uraoka, Toshio, additional

Published
2019
Full Text
View/download PDF

128. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Author

Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Toyoda, Hidenori, Yasuda, Satoshi, Tsuji, Kunihiko, Hatanaka, Takeshi, Kakizaki, Satoru, Naganuma, Atsushi, Ishikawa, Toru, Tada, Toshifumi, Takaguchi, Koichi, Itobayashi, Ei, Shimada, Noritomo, Shibata, Hiroshi, Tanaka, Takaaki, Tsutsui, Akemi, Nagano, Takuya, Imai, Michitaka, and Nakamura, Shinichiro

Subjects
ALPHA fetoproteins, SURVIVAL, CHEMOEMBOLIZATION, RETROSPECTIVE studies, RISK assessment, CANCER patients, DESCRIPTIVE statistics, TUMOR markers, HEPATOCELLULAR carcinoma
Abstract

Background/Aim: With the development of systemic treatment methods for unresectable hepatocellular carcinoma (uHCC), the concept of unsuitable for transcatheter arterial chemoembolization (TACE) has become important. This study aimed to establish a simple predictive scoring system for determining TACE unsuitable status. Materials/Methods: From 1998 to 2015, 196 patients with intermediate-stage uHCC with Child-Pugh A (score 5:6 = 108:88) and given TACE as the initial treatment were enrolled. At the baseline, tumor burden (Milan criteria-out, up-to-7 in/out, and up-to-11 in/out: 0–2 points) and modified albumin-bilirubin grade 1/2a or 2b (0–1 point) were added to determine the score for TACE unsuitable (CITRUS-MICAN score; low <2 and high ≥2). In addition, a previously reported tumor marker (TM) score, in which alpha-fetoprotein (AFP) was ≥100 ng/mL, fucosylated AFP ≥10%, and des-gamma-carboxy prothrombin ≥100 mAU/mL (each 1 point) (total 0, 1, or ≥2 points), was used for additionally evaluating tumor malignancy potential. Prognosis was retrospectively evaluated based on those scores. Results: Median survival time (MST) was better for low compared to high CITRUS-MICAN score (42.0 vs. 26.4 months) (p = 0.002). A 2-step evaluation using the combination of CITRUS-MICAN and TM scores showed an MST of 43.2 months for low CITRUS-MICAN/TM score 0/1 (rank-A) and 39.6 months for low CITRUS-MICAN/TM score ≥2 (rank-B2), while it was 46.8 months for high CITRUS-MICAN/TM score 0 (rank-B1), 28.8 months for high CITRUS-MICAN/TM score 1 (rank-B2), and 22.8 months for high CITRUS-MICAN/TM score ≥2 (rank-C). For rank-A cases (n = 51), MST was 43.2 months, while it was 46.8 months for rank-B1 (n = 12), 31.2 months for rank-B2 (n = 82), and 22.8 months for rank-C (n = 51) (p = 0.001). Conclusion: The results showed that rank-C indicates absolute TACE unsuitable status. For rank-A patients, good prognosis with TACE can be expected, while TACE refractoriness status during the clinical course should be carefully evaluated so as to anticipate the appropriate timing for switching to systemic treatment in rank-B1 and -B2 patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

129. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Aoki, Tomoko, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Hiasa, Yoichi, and Kudo, Masatoshi

Published
2022
Full Text
View/download PDF

132. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33

Author

40252449, 90396862, Hitomi, Yuki, Ueno, Kazuko, Kawai, Yosuke, Nishida, Nao, Kojima, Kaname, Kawashima, Minae, Aiba, Yoshihiro, Nakamura, Hitomi, Kouno, Hiroshi, Kouno, Hirotaka, Ohta, Hajime, Sugi, Kazuhiro, Nikami, Toshiki, Yamashita, Tsutomu, Katsushima, Shinji, Komeda, Toshiki, Ario, Keisuke, Naganuma, Atsushi, Shimada, Masaaki, Hirashima, Noboru, Yoshizawa, Kaname, Makita, Fujio, Furuta, Kiyoshi, Kikuchi, Masahiro, Naeshiro, Noriaki, Takahashi, Hironao, Mano, Yutaka, Yamashita, Haruhiro, Matsushita, Kouki, Tsunematsu, Seiji, Yabuuchi, Iwao, Nishimura, Hideo, Shimada, Yusuke, Yamauchi, Kazuhiko, Komatsu, Tatsuji, Sugimoto, Rie, Sakai, Hironori, Mita, Eiji, Koda, Masaharu, Nakamura, Yoko, Kamitsukasa, Hiroshi, Sato, Takeaki, Nakamuta, Makoto, Masaki, Naohiko, Takikawa, Hajime, Tanaka, Atsushi, Ohira, Hiromasa, Zeniya, Mikio, Abe, Masanori, Kaneko, Shuichi, Honda, Masao, Arai, Kuniaki, Arinaga-Hino, Teruko, Hashimoto, Etsuko, Taniai, Makiko, Umemura, Takeji, Joshita, Satoru, Nakao, Kazuhiko, Ichikawa, Tatsuki, Shibata, Hidetaka, Takaki, Akinobu, Yamagiwa, Satoshi, Seike, Masataka, Sakisaka, Shotaro, Takeyama, Yasuaki, Harada, Masaru, Senju, Michio, Yokosuka, Osamu, Kanda, Tatsuo, Ueno, Yoshiyuki, Ebinuma, Hirotoshi, Himoto, Takashi, Murata, Kazumoto, Shimoda, Shinji, Nagaoka, Shinya, Abiru, Seigo, Komori, Atsumasa, Migita, Kiyoshi, Ito, Masahiro, Yatsuhashi, Hiroshi, Maehara, Yoshihiko, Uemoto, Shinji, Kokudo, Norihiro, Nagasaki, Masao, Tokunaga, Katsushi, Nakamura, Minoru, 40252449, 90396862, Hitomi, Yuki, Ueno, Kazuko, Kawai, Yosuke, Nishida, Nao, Kojima, Kaname, Kawashima, Minae, Aiba, Yoshihiro, Nakamura, Hitomi, Kouno, Hiroshi, Kouno, Hirotaka, Ohta, Hajime, Sugi, Kazuhiro, Nikami, Toshiki, Yamashita, Tsutomu, Katsushima, Shinji, Komeda, Toshiki, Ario, Keisuke, Naganuma, Atsushi, Shimada, Masaaki, Hirashima, Noboru, Yoshizawa, Kaname, Makita, Fujio, Furuta, Kiyoshi, Kikuchi, Masahiro, Naeshiro, Noriaki, Takahashi, Hironao, Mano, Yutaka, Yamashita, Haruhiro, Matsushita, Kouki, Tsunematsu, Seiji, Yabuuchi, Iwao, Nishimura, Hideo, Shimada, Yusuke, Yamauchi, Kazuhiko, Komatsu, Tatsuji, Sugimoto, Rie, Sakai, Hironori, Mita, Eiji, Koda, Masaharu, Nakamura, Yoko, Kamitsukasa, Hiroshi, Sato, Takeaki, Nakamuta, Makoto, Masaki, Naohiko, Takikawa, Hajime, Tanaka, Atsushi, Ohira, Hiromasa, Zeniya, Mikio, Abe, Masanori, Kaneko, Shuichi, Honda, Masao, Arai, Kuniaki, Arinaga-Hino, Teruko, Hashimoto, Etsuko, Taniai, Makiko, Umemura, Takeji, Joshita, Satoru, Nakao, Kazuhiko, Ichikawa, Tatsuki, Shibata, Hidetaka, Takaki, Akinobu, Yamagiwa, Satoshi, Seike, Masataka, Sakisaka, Shotaro, Takeyama, Yasuaki, Harada, Masaru, Senju, Michio, Yokosuka, Osamu, Kanda, Tatsuo, Ueno, Yoshiyuki, Ebinuma, Hirotoshi, Himoto, Takashi, Murata, Kazumoto, Shimoda, Shinji, Nagaoka, Shinya, Abiru, Seigo, Komori, Atsumasa, Migita, Kiyoshi, Ito, Masahiro, Yatsuhashi, Hiroshi, Maehara, Yoshihiko, Uemoto, Shinji, Kokudo, Norihiro, Nagasaki, Masao, Tokunaga, Katsushi, and Nakamura, Minoru

Abstract

Primary biliary cholangitis (PBC) is a chronic and cholestatic autoimmune liver disease caused by the destruction of intrahepatic small bile ducts. Our previous genome-wide association study (GWAS) identified six susceptibility loci for PBC. Here, in order to further elucidate the genetic architecture of PBC, a GWAS was performed on an additional independent sample set, then a genome-wide meta-analysis with our previous GWAS was performed based on a whole-genome single nucleotide polymorphism (SNP) imputation analysis of a total of 4, 045 Japanese individuals (2, 060 cases and 1, 985 healthy controls). A susceptibility locus on chromosome 3q13.33 (including ARHGAP31, TMEM39A, POGLUT1, TIMMDC1, and CD80) was previously identified both in the European and Chinese populations and was replicated in the Japanese population (OR = 0.7241, P = 3.5 × 10⁻⁹). Subsequent in silico and in vitro functional analyses identified rs2293370, previously reported as the top-hit SNP in this locus in the European population, as the primary functional SNP. Moreover, e-QTL analysis indicated that the effector gene of rs2293370 was Protein O-Glucosyltransferase 1 (POGLUT1) (P = 3.4 × 10⁻⁸). This is the first study to demonstrate that POGLUT1 and not CD80 is the effector gene regulated by the primary functional SNP rs2293370, and that increased expression of POGLUT1 might be involved in the pathogenesis of PBC.

Published
2019

135. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Uehara, Daisuke, additional, Nagashima, Tamon, additional, Ueno, Takashi, additional, Namikawa, Masashi, additional, Saito, Shuichi, additional, Hosonuma, Kenichi, additional, Suzuki, Hideyuki, additional, Naganuma, Atsushi, additional, Takagi, Hitoshi, additional, Sato, Ken, additional, and Uraoka, Toshio, additional

Published
2019
Full Text
View/download PDF

138. Adenosquamous Carcinoma of the Choledochus

Author

Uehara, Daisuke, primary, Takagi, Hitoshi, additional, Hoshino, Takashi, additional, Suzuki, Yuhei, additional, Takakusagi, Satoshi, additional, Maruhashi, Kyoko, additional, Kizawa, Kazuko, additional, Kosone, Takashi, additional, Naganuma, Atsushi, additional, Hisanaga, Etsuko, additional, Hirato, Junko, additional, Kakizaki, Satoru, additional, and Uraoka, Toshio, additional

Published
2019
Full Text
View/download PDF

139. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand–Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma

Author

NAGANUMA, ATSUSHI, primary, HOSHINO, TAKASHI, additional, OHNO, NOZOMI, additional, OGAWA, YUSUKE, additional, MURAKAMI, TATSUMA, additional, HORIGUCHI, SUGURU, additional, UEHARA, DAISUKE, additional, SUZUKI, YUHEI, additional, HATANAKA, TAKESHI, additional, KUDO, TOMOHIRO, additional, ISHIHARA, HIROSHI, additional, SATO, KEN, additional, KAKIZAKI, SATORU, additional, and TAKAGI, HITOSHI, additional

Published
2018
Full Text
View/download PDF

140. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.

Author

Hatanaka, Takeshi, Naganuma, Atsushi, Shibasaki, Mitsuhiko, Kohga, Tatsuya, Arai, Yosuke, Nagashima, Tamon, Ueno, Takashi, Namikawa, Masashi, Saito, Shuichi, Hoshino, Takashi, Takizawa, Daichi, Arai, Hirotaka, Makita, Fujio, Kakizaki, Satoru, Harimoto, Norifumi, Shirabe, Ken, and Uraoka, Toshio

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *ALBUMINS, *DRUG efficacy, *SURVIVAL, *RETROSPECTIVE studies, *DISEASE incidence, *TREATMENT effectiveness, *TUMOR classification, *DESCRIPTIVE statistics, *STATISTICAL correlation, *BILIRUBIN, *HEPATOCELLULAR carcinoma, *PATIENT safety
Abstract

Aim: The aim of this retrospective study was to investigate the efficacy and safety of ramucirumab treatment under real-world conditions and to clarify the role of albumin-bilirubin (ALBI) score in predicting outcomes. Methods: Between June 2019 and May 2020, a total of 16 patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab in Gunma Saiseikai Maebashi Hospital and its affiliated hospitals was included. Results: The median age was 71 (interquartile range [IQR] 65–74) years old, and 12 patients (75.0%) were male. The modified ALBI (mALBI) grade was 1, 2a, and 2b at baseline in 4 (25.0%), 3 (18.8%), and 9 patients (56.3%), respectively. The Barcelona Clinic Liver Cancer stage was intermediate and advanced stage in 1 (6.3%) and 15 patients (93.8%), respectively. The serum α-fetoprotein at baseline was 4,911 (IQR 2,091–17,377) ng/mL. The disease control rate in patients with mALBI grade1 + 2a was significantly higher than in those with mALBI grade 2b (100 vs. 28.6%, p = 0.028). The patients with mALBI grade 1 + 2a had a significantly better overall survival (OS) and longer progression-free survival (PFS) than those with mALBI grade 2b (median OS 6.7 vs. 3.0 months; p = 0.036, median PFS 7.5 vs. 1.4 months; p = 0.002). The number of cycles of ramucirumab treatment was significantly correlated with the ALBI score (r = −0.452, p = 0.030). The patients with mALBI grade 1 + 2a showed a low incidence of adverse events (AEs) and discontinuation due to AEs. Conclusions: Advanced HCC patients with mALBI grade 1 + 2a may be a good indication for ramucirumab treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

142. The development of broncho-biliary fistula after treatment for hepatocellular carcinoma: a report of two cases.

Author

Takakusagi, Satoshi, Hoshino, Takashi, Takagi, Hitoshi, Naganuma, Atsushi, Yokoyama, Yozo, Kizawa, Kazuko, Marubashi, Kyoko, Kosone, Takashi, Watanabe, Akira, Kubo, Norio, Araki, Kenichiro, Harimoto, Norifumi, Shirabe, Ken, Nobusawa, Sumihito, Zennyoji, Dan, Shimizu, Takehiro, Sato, Ken, Kakizaki, Satoru, and Uraoka, Toshio

Abstract

Broncho-biliary fistula (BBF) is a rare but severe disorder defined as abnormal communication between the biliary system and bronchial tree. Cases of BBF have occasionally been reported, but no standard treatment has been established. We report two cases of BBF that developed after the treatment of hepatocellular carcinoma (HCC) and reviewed the relevant literature. Case 1, a man in his early eighties was diagnosed with BBF 4 months after undergoing surgical resection for HCC (diameter, 7 cm; location, segments 4 and 5). Percutaneous drainage and endoscopic nasobiliary drainage (ENBD) improved BBF without recurrence for more than a year. Case 2, a woman in her late sixties was diagnosed with BBF after percutaneous radiofrequency ablation for HCC. Although the BBF was treated with ENBD, bronchial occlusion, and percutaneous transhepatic portal vein embolization, these treatments were unsuccessful and the patient died. Although non-invasive treatments have been developed, refractory BBF still exists. The prediction of BBF and the development of more effective treatments are necessary to improve outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

143. Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.

Author

Takaoka, Yoshinari, Miura, Kouichi, Morimoto, Naoki, Ikegami, Tadashi, Kakizaki, Satoru, Sato, Ken, Ueno, Takashi, Naganuma, Atsushi, Kosone, Takashi, Arai, Hirotaka, Hatanaka, Takeshi, Tahara, Toshiyuki, Tano, Shigeo, Ohtake, Takaaki, Murohisa, Toshimitsu, Namikawa, Masashi, Asano, Takeharu, Kamoshida, Toshiro, Horiuchi, Katsuhiko, and Nihei, Takeshi

Subjects
DRUG efficacy, HEPATITIS C virus, CIRRHOSIS of the liver, VIRUS diseases, HEPATITIS C, SOFOSBUVIR
Abstract

Aim: This study aimed to evaluate the real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir (SOF/VEL) treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus (HCV) infection. Methods: A total 72 of patients with Child–Pugh (CP) class B or C were enrolled. We evaluated the sustained virologic response at 12 weeks after the end of treatment (SVR12), adverse events (AEs), and changes in the liver function. Results: All participants had genotype 1 or 2 HCV infection. At baseline, the numbers of patients with CP class B and C were 59 and 13, respectively. The overall SVR12 rate was 95.8% (69/72); 94.9% (56/59) in CP class B and 100% (13/13) in CP class C. The serum albumin level, prothrombin time and ascites were significantly improved (P < 0.01); however, the serum bilirubin level and encephalopathy did not improve. Among patients who achieved SVR12, 75.0% showed an improvement in their CP score, while 5.9% showed a worsening. The presence of large portosystemic shunt (diameter ≥6 mm) and hyperbilirubinemia (≥2.0 mg/dL) were independent factors that interfered with the improvement in the CP score (P < 0.05). The most common AEs were encephalopathy (15.3%) and skin symptoms (7.9%). Two patients discontinued SOF/VEL due to AEs. Conclusions: Treatment with SOF/VEL for 12 weeks was relatively safe and effective for patients with decompensated cirrhosis. An SVR provided an improvement of the liver function in the majority of patients. However, large portosystemic shunt and hyperbilirubinemia were independent factors that interfered with the improvement in the CP score. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

144. Prediction of oral intake recovery for inpatients with aspiration pneumonia by videoendoscopic evaluation using the Hyodo‐Komagane score in Japan.

Author

Kimura, Masanori, Nakayama, Enri, Ogawa, Yusuke, Sato, Mari, Inagawa, Motoaki, Watanabe, Mao, Sato, Mitsuyasu, Naganuma, Atsushi, Ogawa, Tetsushi, and Ueda, Koichiro

Subjects
ASPIRATION pneumonia, ENDOSCOPY, DEGLUTITION, INGESTION, VIDEO recording, LOGISTIC regression analysis, ODDS ratio
Abstract

Objective: To verify the validity of the prediction of oral intake recovery for inpatients with aspiration pneumonia using the Hyodo‐Komagane score. Background: Patients admitted for treatment of aspiration pneumonia sometimes have difficulty in resuming oral intake due to decreased swallowing function. Predicting whether the swallowing function will recover enough to achieve oral ingestion at discharge is an important factor in developing a treatment strategy. No studies have investigated the prediction of oral intake recovery using videoendoscopic examination. Methods: Subjects were 65 patients who were admitted to an acute care hospital for the treatment of aspiration pneumonia. The patients were divided into two groups, the oral feeding group and the tube feeding group, according to their oral intake status at discharge or transfer. Logistic regression analysis was performed using the condition that tube feeding was not required as an objective variable and the items with significant differences between the two groups as explanatory variables. Additionally, the receiver operating characteristic curve was used to identify patients who could take food orally at discharge. Results: The odds ratios for the Hyodo‐Komagane score and the pharyngeal clearance score were 1.485 and 3.379, respectively. When the cut‐off values of the Hyodo‐Komagane score and the pharyngeal clearance score were 6 and 1, the sensitivity was 0.88 and 0.91, and the specificity was 0.64 and 0.70, respectively. Conclusion: The Hyodo‐Komagane score and especially the pharyngeal clearance score are useful indices to predict oral intake recovery for inpatients with aspiration pneumonia. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

146. Integrated GWAS and mRNA Microarray Analysis Identified IFNG and CD40L as the Central Upstream Regulators in Primary Biliary Cholangitis.

Author

Ueno, Kazuko, Aiba, Yoshihiro, Hitomi, Yuki, Shimoda, Shinji, Nakamura, Hitomi, Gervais, Olivier, Kawai, Yosuke, Kawashima, Minae, Nishida, Nao, Kohn, Seik‐Soon, Kojima, Kaname, Katsushima, Shinji, Naganuma, Atsushi, Sugi, Kazuhiro, Komatsu, Tatsuji, Mannami, Tomohiko, Matsushita, Kouki, Yoshizawa, Kaname, Makita, Fujio, and Nikami, Toshiki

Subjects
MESSENGER RNA, CHOLANGITIS
Abstract

Genome‐wide association studies (GWASs) in European and East Asian populations have identified more than 40 disease‐susceptibility genes in primary biliary cholangitis (PBC). The aim of this study is to computationally identify disease pathways, upstream regulators, and therapeutic targets in PBC through integrated GWAS and messenger RNA (mRNA) microarray analysis. Disease pathways and upstream regulators were analyzed with ingenuity pathway analysis in data set 1 for GWASs (1,920 patients with PBC and 1,770 controls), which included 261 annotated genes derived from 6,760 single‐nucleotide polymorphisms (P < 0.00001), and data set 2 for mRNA microarray analysis of liver biopsy specimens (36 patients with PBC and 5 normal controls), which included 1,574 genes with fold change >2 versus controls (P < 0.05). Hierarchical cluster analysis and categorization of cell type–specific genes were performed for data set 2. There were 27 genes, 10 pathways, and 149 upstream regulators that overlapped between data sets 1 and 2. All 10 pathways were immune‐related. The most significant common upstream regulators associated with PBC disease susceptibility identified were interferon‐gamma (IFNG) and CD40 ligand (CD40L). Hierarchical cluster analysis of data set 2 revealed two distinct groups of patients with PBC by disease activity. The most significant upstream regulators associated with disease activity were IFNG and CD40L. Several molecules expressed in B cells, T cells, Kupffer cells, and natural killer–like cells were identified as potential therapeutic targets in PBC with reference to a recently reported list of cell type–specific gene expression in the liver. Conclusion: Our integrated analysis using GWAS and mRNA microarray data sets predicted that IFNG and CD40L are the central upstream regulators in both disease susceptibility and activity of PBC and identified potential downstream therapeutic targets. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

147. Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Nagashima, Tamon, Namikawa, Masashi, Tojima, Hiroki, Shimada, Yasushi, Takizawa, Daichi, Naganuma, Atsushi, Arai, Hirotaka, Sato, Ken, Harimoto, Norifumi, Shirabe, Ken, and Uraoka, Toshio

Subjects
HEPATOCELLULAR carcinoma, PROGRESSION-free survival, ADVERSE health care events, TUMOR classification, LIVER cancer
Abstract

Aim: The aim of this study was to investigate the predictive factors of objective response rate (ORR) and progression‐free survival (PFS), and the correlation of albumin‐bilirubin (ALBI) grade with decreased appetite and fatigue in hepatocellular carcinoma patients treated with lenvatinib. Methods: From March 2018 to December 2018, a total of 94 patients was included in this retrospective multicenter study. Results: The median age of all patients was 73 years (interquartile range 66–79.3 years), and approximately 78% patients were men. The ALBI grade was 1, 2, and 3 in 27 (28.7%), 64 (68.1%), and three patients (3.2%), respectively. The Barcelona Clinic Liver Cancer stage was early, intermediate, and advanced in one (1.1%), 22 (23.4%), and 71 patients (75.5%), respectively. Best radiological response was determined to complete response, partial response, stable disease, and progressive disease in 0 (0.0%), 24 (30.4%), 38 (48.1%), and 17 patients (21.5%), respectively, giving the ORR of 30.4%. The 3‐, 6‐, and 12‐month PFS was calculated to be 78.7% (95% CI 70.3–87.1%), 46.7% (95% CI 36.1–57.3%), and 17.4% (95% CI 6.6–28.2%). Multivariate analysis showed that the Barcelona Clinic Liver Cancer intermediate stage was shown to be the only significant factor affecting the ORR (odds ratio 3.78, 95% CI 1.14–12.5, P = 0.030) and PFS (hazard ratio 0.49, 95% CI 0.26–0.94, P = 0.030). The incidence of all grades of decreased appetite and fatigue was significantly less in patients with ALBI grade 1 compared with ALBI grade 2 + 3. Conclusions: The Barcelona Clinic Liver Cancer intermediate stage was the predictive factor affecting the ORR and PFS, and ALBI grade was a good predictive factor affecting the incidence of fatigue and decreased appetite. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

148. Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.

Author

Tojima, Hiroki, Kakizaki, Satoru, Takakusagi, Satoshi, Hoshino, Takashi, Naganuma, Atsushi, Nagashima, Tamon, Namikawa, Masashi, Ueno, Takashi, Shimada, Yasushi, Hatanaka, Takeshi, Takizawa, Daichi, Arai, Hirotaka, Sato, Ken, Takagi, Hitoshi, and Uraoka, Toshio

Subjects
HEPATITIS C, HEPATITIS C virus, DRUG resistance, AMINO acids
Abstract

Aim: In patients with hepatitis C virus, treatment failure of daclatasvir plus asunaprevir combination therapy (DCV + ASV) seems to become intractable due to the induction of resistance‐associated substitutions. This study aimed to investigate the outcomes of retreatment with direct‐acting antivirals (DAAs) in patients with DCV + ASV therapy failure, as well as changes in drug resistance mutations. Methods: We retrospectively analyzed 44 patients re‐treated with DAAs after DCV + ASV failure between December 2015 and April 2018. All patients were analyzed for amino acid substitutions, and additional treatment regimens were selected based on the results and current treatment guidelines. Results: The sustained virological response rate with second‐line treatment was 81.8% (36/44), and relapse occurred in five of 16 patients who received sofosbuvir/ledipasvir and three of seven patients who received DCV/ASV/beclabuvir. Third‐ and fourth‐line treatments were also tried in relapsed cases, and the overall sustained virological response rates were 90.9% (40/44) and 93.2% (41/44), respectively. A high rate of viral clearance was eventually observed. Before second‐line treatment, the prevalence of mutations in the NS5A and NS3/4A regions was 100% (44/44) and 86.4% (38/44), respectively. There was no significant increase in the number of amino acid substitutions in patients for whom second‐line treatment failed. Conclusions: Amino acid substitutions were frequently observed in patients with DCV + ASV failure, but most patients achieved a sustained virological response after retreatment with DAAs. Although the spread of drug‐resistant viruses due to unsuccessful DAA treatment was a matter of concern, most cases of DCV + ASV failure were overcome with additional treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

149. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial

Author

Suzuki, Kazuyuki, primary, Endo, Ryujin, additional, Takikawa, Yasuhiro, additional, Moriyasu, Fuminori, additional, Aoyagi, Yutaka, additional, Moriwaki, Hisataka, additional, Terai, Shuji, additional, Sakaida, Isao, additional, Sakai, Yoshiyuki, additional, Nishiguchi, Shuhei, additional, Ishikawa, Toru, additional, Takagi, Hitoshi, additional, Naganuma, Atsushi, additional, Genda, Takuya, additional, Ichida, Takafumi, additional, Takaguchi, Koichi, additional, Miyazawa, Katsuhiko, additional, and Okita, Kiwamu, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results